Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO5024048 + pegylated interferon + ribavirin
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
**RO5024048 + pegylated interferon + ribavirin** is a triple combination regimen investigated primarily for the treatment of chronic hepatitis C infection. RO5024048 (also known as mericitabine) is an oral prodrug of a cytidine nucleoside analogue that acts as a selective inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. **Pegylated interferon** (including peginterferon alfa-2a and peginterferon alfa-2b) is a long-acting interferon that exerts antiviral, immunomodulatory, and antiproliferative effects, enhancing the immune response against viral infections. **Ribavirin** is a nucleoside analogue with broad-spectrum antiviral activity, used to augment the efficacy of interferon in hepatitis C therapy. The combination aims to increase sustained virological response rates compared to dual therapy regimens.
- Other names
- mericitabinepeginterferon alfa-2apeginterferon alfa-2bribavirin
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on RO5024048 + pegylated interferon + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO5024048 + pegylated interferon + ribavirin.